Related Experiment Videos
Structurally modified ibogaine analogs exhibit differing affinities for NMDA receptors
R T Layer1, P Skolnick, C M Bertha
1Laboratory of Neuroscience, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892-0008, USA. rtlayer@helix.nih.gov
European Journal of Pharmacology
|August 8, 1996
Summary
Ibogaine shows anti-addictive properties by blocking NMDA receptors. This study investigated ibogaine analogs, finding ibogaine most potent in inhibiting NMDA receptors and reducing withdrawal symptoms in mice.
Area of Science:
- Neuroscience
- Pharmacology
- Addiction Research
Background:
- Ibogaine, a psychoactive indole alkaloid, is recognized for potential anti-addictive properties.
- Previous research suggests that N-methyl-D-aspartate (NMDA) receptor blockade may underlie ibogaine's anti-addiction effects.
Purpose of the Study:
- To evaluate the potency of ibogaine analogs in inhibiting NMDA receptors.
- To investigate the relationship between NMDA receptor antagonism and the anti-addiction effects of ibogaine in preclinical models.
Main Methods:
- Examined the inhibitory effects of ibogaine and its analogs on (+)-[3-3H]5-methyl-10,11-dihydro-5H-dibenzo-[a,d]cyclohepten-5,10-imine ([3H]MK-801) binding to NMDA receptors.
- Tested the efficacy of ibogaine, O-desmethylibogaine, and O-t-butyl-O-desmethylibogaine in attenuating naloxone-precipitated withdrawal jumping in morphine-dependent mice.
Main Results:
- Ibogaine demonstrated the highest potency in inhibiting [3H]MK-801 binding (Ki ≈ 1.2 µM).
- Structurally similar analogs, O-desmethylibogaine and O-t-butyl-O-desmethylibogaine, were less potent inhibitors (Ki ≈ 5.5 µM and 179.0 µM, respectively).
- Ibogaine, but not its analogs, significantly attenuated morphine withdrawal symptoms in mice.
Conclusions:
- The findings support the hypothesis that ibogaine's ability to inhibit morphine dependence is linked to its NMDA receptor antagonist properties.
- NMDA receptor antagonism is a key mechanism underlying the anti-addiction potential of ibogaine.